Alnylam Pharmaceuticals Presents New Pre-clinical Data on ALN-AAT, an RNAi Therapeutic Targeting Alpha-1-Antitrypsin (AAT) for the Treatment of AAT Deficiency Liver Disease

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in development for the treatment of liver disease associated with AAT deficiency. These data were presented in a poster entitled “Developing an RNAi Therapeutic for Liver Disease Associated with Alpha-1-Antitrypsin Deficiency” at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, “The Liver Meeting”) held November 1 – 5, 2013 in Washington, D.C. AAT deficiency liver disease is a rare genetic disorder, with the most common mutation being in the “Z-allele,” which results in the accumulation of the mutant AAT protein (Z-AAT) in liver tissue with subsequent liver injury, fibrosis, and, in some cases, hepatocellular carcinoma. There are approximately 12,000 people in the U.S. and E.U. with liver pathology associated with AAT deficiency.

Help employers find you! Check out all the jobs and post your resume.